100% Clinical improvement, 50% Remission in BED study
Filed with ASX · · 11 pages · English
Entropy Neurodynamics Limited on 6ix
In the deck
Story so far
Earlier from Entropy Neurodynamics
- DSMB Clears TRP 8803 to Advance to Cohort 2
- Entropy completes Cohort 1 dosing in BED trial
- Entropy files new US patent for IBS program
- TRP 8802 delivers 75% breakthrough response in IBS
- TRP-8803 delivers repeatable, high-intensity effect
Later from Entropy Neurodynamics
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
- Trading Halt
- 72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
- 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
- BioShares 2026 Investor Presentation Deck
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics